Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose intravenous magnesium sulfate after gastrointestinal cancer surgery
IRCT20120216009045N7Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-blind trial of magnesium sulfate in gastrointestinal cancer (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Improvement in clinical symptoms related to inflammation after gastrointestinal cancer surgery and Control of postoperative inflammation. Started Nov 2024; status: completed.
02
Drugs
magnesium sulfate
03
Conditions
gastrointestinal cancer
Beyond the preview
Go deeper on IRCT20120216009045N7.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120216009045N7.